PD-L1 Expression Is a Prognostic Factor in Patients with Thoracic Esophageal Cancer Treated Without Adjuvant Chemotherapy

被引:30
作者
Wakita, Akiyuki [1 ]
Motoyama, Satoru [1 ]
Nanjo, Hiroshi [2 ]
Sato, Yusuke [1 ]
Yoshino, Kei [1 ]
Sasaki, Tomohiko [1 ]
Kawakita, Yuta [1 ]
Liu, Jiajia [1 ]
Imai, Kazuhiro [1 ]
Saito, Hajime [1 ]
Minamiya, Yoshihiro [1 ]
机构
[1] Akita Univ, Grad Sch Med, Dept Thorac Surg, 1-1-1 Hondo, Akita 0108543, Japan
[2] Akita Univ, Grad Sch Med, Dept Pathol, Akita, Japan
关键词
PD-L1; esophageal cancer; prognosis; immunochemistry; LIGAND; 1; PD-L1; TUMOR-INFILTRATING LYMPHOCYTES; RENAL-CELL CARCINOMA; T-CELLS; PROGRAMMED DEATH-1; POOR-PROGNOSIS; B7; FAMILY; B7-H1; SURVIVAL; MOLECULE;
D O I
10.21873/anticanres.11467
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: Programmed death- 1 ligand 1 (PD-L1) induces apoptosis of tumor-reactive T-cells, that enables tumors to evade immune defense and thus furthers their growth. Our aim was to determine whether PD-L1 expression status correlates with prognosis in patients with advanced thoracic esophageal squamous cell carcinoma. Patients and Methods: The PD-L1 expression status of 177 patients treated with esophagectomy without preoperative therapy was evaluated immunohistochemically using tissue microarray. We then statistically analyzed the relationships between PD-L1 expression status and clinicopathological features and survival. Results: In patients undergoing surgery alone, PD-L1 expression was significantly positivity associated with a better prognosis. By contrast, there were no significant correlations between PD-L1 expression and clinicopathological features or outcomes in patients treated with surgery plus postoperative adjuvant chemotherapy. Conclusion: PD-L1 positivity in advanced thoracic esophageal squamous cell carcinoma may be predictive of a positive prognosis in patients treated without adjuvant chemotherapy.
引用
收藏
页码:1433 / 1441
页数:9
相关论文
共 50 条
  • [11] Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
    Curiel, TJ
    Coukos, G
    Zou, LH
    Alvarez, X
    Cheng, P
    Mottram, P
    Evdemon-Hogan, M
    Conejo-Garcia, JR
    Zhang, L
    Burow, M
    Zhu, Y
    Wei, S
    Kryczek, I
    Daniel, B
    Gordon, A
    Myers, L
    Lackner, A
    Disis, ML
    Knutson, KL
    Chen, LP
    Zou, WP
    [J]. NATURE MEDICINE, 2004, 10 (09) : 942 - 949
  • [12] Dong HD, 1999, NAT MED, V5, P1365
  • [13] Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730
  • [14] Clinical impact of programmed cell death ligand 1 expression in colorectal cancer
    Droeser, Raoul A.
    Hirt, Christian
    Viehl, Carsten T.
    Frey, Daniel M.
    Nebiker, Christian
    Huber, Xaver
    Zlobec, Inti
    Eppenberger-Castori, Serenella
    Tzankov, Alexander
    Rosso, Raffaele
    Zuber, Markus
    Muraro, Manuele Giuseppe
    Amicarella, Francesca
    Cremonesi, Eleonora
    Heberer, Michael
    Iezzi, Giandomenica
    Lugli, Alessandro
    Terracciano, Luigi
    Sconocchia, Giuseppe
    Oertli, Daniel
    Spagnoli, Giulio C.
    Tornillo, Luigi
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (09) : 2233 - 2242
  • [15] Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
    Freeman, GJ
    Long, AJ
    Iwai, Y
    Bourque, K
    Chernova, T
    Nishimura, H
    Fitz, LJ
    Malenkovich, N
    Okazaki, T
    Byrne, MC
    Horton, HF
    Fouser, L
    Carter, L
    Ling, V
    Bowman, MR
    Carreno, BM
    Collins, M
    Wood, CR
    Honjo, T
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (07) : 1027 - 1034
  • [16] COMBINED CHEMOTHERAPY AND RADIOTHERAPY COMPARED WITH RADIOTHERAPY ALONE IN PATIENTS WITH CANCER OF THE ESOPHAGUS
    HERSKOVIC, A
    MARTZ, K
    ALSARRAF, M
    LEICHMAN, L
    BRINDLE, J
    VAITKEVICIUS, V
    COOPER, J
    BYHARDT, R
    DAVIS, L
    EMAMI, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (24) : 1593 - 1598
  • [17] INDUCED EXPRESSION OF PD-1, A NOVEL MEMBER OF THE IMMUNOGLOBULIN GENE SUPERFAMILY, UPON PROGRAMMED CELL-DEATH
    ISHIDA, Y
    AGATA, Y
    SHIBAHARA, K
    HONJO, T
    [J]. EMBO JOURNAL, 1992, 11 (11) : 3887 - 3895
  • [18] Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
    Iwai, Y
    Ishida, M
    Tanaka, Y
    Okazaki, T
    Honjo, T
    Minato, N
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (19) : 12293 - 12297
  • [19] LYMPHOCYTIC INFILTRATION AND SURVIVAL IN RECTAL-CANCER
    JASS, JR
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1986, 39 (06) : 585 - 589
  • [20] PD-L2 is a second ligand for PD-I and inhibits T cell activation
    Latchman, Y
    Wood, CR
    Chernova, T
    Chaudhary, D
    Borde, M
    Chernova, I
    Iwai, Y
    Long, AJ
    Brown, JA
    Nunes, R
    Greenfield, EA
    Bourque, K
    Boussiotis, VA
    Carter, LL
    Carreno, BM
    Malenkovich, N
    Nishimura, H
    Okazaki, T
    Honjo, T
    Sharpe, AH
    Freeman, GJ
    [J]. NATURE IMMUNOLOGY, 2001, 2 (03) : 261 - 268